Methods and compositions for inducing hematopoietic cell differentiation
AssigneeFate Therapeutics, Inc.
InventorsBahram Valamehr, Raedun Clarke, Ryan Bjordahl
Life of this patent
Estimating the term…
Abstract
The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.
Claims20
A method of generating pluripotent stem cell derived definitive hemogenic endothelium (HE) cells, comprising culturing pluripotent stem cell derived mesodermal cells having definitive hemogenic endothelium (HE) potential in a medium comprising a GSK3 inhibitor to obtain definitive HE cells, wherein the obtained definitive HE cells:
- (i) are increased in numbers and percentage in cell population;
- (ii) have increased potency in differentiation;
- and/or
- (iii) improved HE cellularity,
- as compared to culturing without the GSK3 inhibitor.
Dependencies are inferred from the claim text.